COMMUNIQUÉS West-GlobeNewswire

Vericel to Report Second-Quarter 2024 Financial Results on August 1, 2024

18/07/2024 - 14:30

CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second- [...]

Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15

18/07/2024 - 14:25

Nose-to-Brain Drug Delivery Shows Promising Patient Safety and Therapeutic Benefit The Device and CMC Development Master Plan is designed to support IND-enabling studies SARASOTA, FL, July 18, 2024 (GLOBE NEWSWIRE) -- [...]

NKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer’s Association International Conference

18/07/2024 - 14:05

SANTA ANA, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative [...]

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

18/07/2024 - 14:00

VOQUEZNA is now approved and available to treat the largest category of Gastroesophageal Reflux Disease (GERD) VOQUEZNA met its primary endpoint in its Phase 3 pivotal trial by demonstrating a significant and rapid [...]

Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy

18/07/2024 - 14:00

BALTIMORE, Md. and BASKING RIDGE, N.J., July 18, 2024 (GLOBE NEWSWIRE) -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, and Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company [...]

Inovalon’s Converged Quality Achieves 24th Consecutive NCQA HEDIS® Certification

18/07/2024 - 14:00

The Company’s Solutions are Trusted by the Health Plans Representing 80% of all U.S. Covered Lives to Deliver HEDIS Results on Time, Improving Clinical Quality and Member Outcomes BOWIE, Md., July 18, 2024 (GLOBE [...]

Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform

18/07/2024 - 14:00

SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today [...]

Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor

18/07/2024 - 14:00

BOTHELL, Wash., July 18, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) today reported favorable safety and tolerability results from the single-ascending dose (SAD) [...]

OPKO Health Announces $100 Million Share Repurchase Program

18/07/2024 - 14:00

MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized the repurchase of up to $100 million of shares of the Company's common stock. Under the [...]

Rapid Micro Biosystems to Announce Second Quarter 2024 Financial Results on August 2, 2024

17/07/2024 - 22:30

LOWELL, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate [...]

Teladoc Health to Announce Second Quarter 2024 Financial Results

17/07/2024 - 22:30

PURCHASE, NY, July 17, 2024 (GLOBE NEWSWIRE) -- Teladoc Health , Inc. (NYSE: TDOC), the global leader in whole-person virtual care, announced that it will release second quarter 2024 results on Wednesday, July 31, 2024 [...]

Scorpius Holdings Announces Reverse Stock Split

17/07/2024 - 22:30

DURHAM, N.C., July 17, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today announced [...]

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal

17/07/2024 - 22:15

-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval [...]

OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA’s Profit Share Payments

17/07/2024 - 22:14

MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces it has entered into a $250 million non-dilutive note purchase agreement with HealthCare Royalty (HCRx) secured by OPKO’s profit share [...]

Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma

17/07/2024 - 22:14

Minimally Invasive treatment with ExoPTEN showed functional restoration of damaged eyes to healthy levels in animals TORONTO and HAIFA, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), ( [...]

ClearPoint Neuro to Announce Second Quarter 2024 Results August 7, 2024

17/07/2024 - 22:05

SOLANA BEACH, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine [...]

Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program

17/07/2024 - 22:05

Alignment with FDA on Phase 3 study primary endpoint of Bayley-4 cognition and key secondary endpoint of Multi-Domain Responder Index (MDRI) Phase 3 study on track to initiate by the end of this year NOVATO, Calif., [...]

Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion

17/07/2024 - 22:00

Participants completed primary vaccination series (3 doses) with VLA15 Primary vaccination series to be followed by a booster approximately one year after completion New York, NY and Saint-Herblain (France), July 17, [...]

Essai de Phase 3 VALOR sur la maladie de Lyme : Valneva et Pfizer finalisent la vaccination primaire de tous les participants

17/07/2024 - 22:00

Les participants à l’essai ont reçu les trois doses de VLA15 de la vaccination primaire Une vaccination de rappel sera effectuée environ un an après la date d’achèvement de la vaccination primaire New York, NY et Saint- [...]